We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

83 hedge funds and large institutions have $56.7M invested in Relmada Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

26% more capital invested

Capital invested by funds: $45M → $56.7M (+$11.8M)

4.25% less ownership

Funds ownership: 49.8% → 45.55% (-4.3%)

5% less funds holding

Funds holding: 87 → 83 (-4)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

79% less call options, than puts

Call options by funds: $296K | Put options by funds: $1.41M

Holders
83
Holders Change
-4
Holders Change %
-4.6%
% of All Funds
1.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
27
Reduced
19
Closed
16
Calls
$296K
Puts
$1.41M
Net Calls
-$1.12M
Net Calls Change
-$342K

Top Buyers

1
OM
Opaleye Management
Massachusetts
+$2.51M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$740K
3
Deutsche Bank
Deutsche Bank
Germany
+$651K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$485K
5
Marshall Wace
Marshall Wace
United Kingdom
+$455K

Top Sellers

1
RI
RTW Investments
New York
-$6.4M
2
DTC
Deep Track Capital
Connecticut
-$2.35M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$478K
4
SSA
Schonfeld Strategic Advisors
New York
-$328K
5
Voloridge Investment Management
Voloridge Investment Management
Florida
-$274K
Name Holding Trade Value Shares
Change 		Change in
Stake
DTC
1
Deep Track Capital
Connecticut
$8.46M -$2.35M -793,311 -28%
Vanguard Group
2
Vanguard Group
Pennsylvania
$5.43M +$2.28K +770 +0.1%
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$4.89M +$29.9K +10,102 +0.9%
PCM
4
Parsons Capital Management
Rhode Island
$3.93M -$71.8K -24,241 -2%
OM
5
Opaleye Management
Massachusetts
$3.63M +$2.51M +847,000 +2,823%
PAI
6
Palo Alto Investors
California
$3.03M – – –
BlackRock
7
BlackRock
New York
$2.37M -$4.04K -1,364 -0.2%
Citadel Advisors
8
Citadel Advisors
Florida
$1.56M -$167K -56,437 -13%
Two Sigma Advisers
9
Two Sigma Advisers
New York
$1.36M +$485K +163,900 +100%
Two Sigma Investments
10
Two Sigma Investments
New York
$1.25M +$313K +105,547 +54%
Mirae Asset Global Investments
11
Mirae Asset Global Investments
South Korea
$1.12M +$33.7K +11,387 +4%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$1.03M +$740K +250,000 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$1.01M +$10.4K +3,509 +1%
Deutsche Bank
14
Deutsche Bank
Germany
$931K +$651K +219,887 +4,434%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$884K +$260K +87,774 +70%
GIM
16
Guild Investment Management
California
$878K +$20.1K +6,800 +3%
Bank of America
17
Bank of America
North Carolina
$872K -$8.6K -2,904 -1%
Millennium Management
18
Millennium Management
New York
$823K -$134K -45,300 -19%
GCP
19
GSA Capital Partners
United Kingdom
$764K -$32.1K -10,842 -6%
Morgan Stanley
20
Morgan Stanley
New York
$746K +$168K +56,883 +46%
BCM
21
Bridgeway Capital Management
Texas
$704K +$202K +68,075 +67%
RC
22
RBF Capital
California
$685K -$84.7K -28,600 -15%
Group One Trading
23
Group One Trading
Illinois
$656K -$6.15K -2,076 -1%
Marshall Wace
24
Marshall Wace
United Kingdom
$636K +$455K +153,525 New
Renaissance Technologies
25
Renaissance Technologies
New York
$608K +$242K +81,614 +125%
1
2 3 4

RLMD Hedge Fund Activity: Q4 2023 in Review

83 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2023, worth a combined $56.7M — up 26% from $45M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RLMD and 14 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 27 added.

The largest buyer was Opaleye Management, adding an estimated $2.51M. The largest seller was RTW Investments, exiting entirely with an estimated $6.4M sold.

  • 83 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2023, down from 87 in Q3 2023.
  • Funds reported $56.7M of Relmada Therapeutics stock for Q4 2023, up 26% quarter-over-quarter.
  • 14 funds opened new Relmada Therapeutics positions in Q4 2023 and 16 closed out, a net change of -2 holders.
  • The largest Relmada Therapeutics buyer in Q4 2023 was Opaleye Management, an estimated $2.51M added.
  • The largest Relmada Therapeutics seller in Q4 2023 was RTW Investments, an estimated $6.4M sold.

Based on aggregated 13F filings for Q4 2023.